Latest news with #prescriptiondrugs
Yahoo
42 minutes ago
- Business
- Yahoo
Why McKesson (MCK) Dipped More Than Broader Market Today
McKesson (MCK) closed the most recent trading day at $693.54, moving -2.99% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.37%. Meanwhile, the Dow experienced a drop of 0.74%, and the technology-dominated Nasdaq saw a decrease of 0.03%. Shares of the prescription drug distributor have appreciated by 1.34% over the course of the past month, outperforming the Medical sector's loss of 0.88%, and lagging the S&P 500's gain of 2.68%. Market participants will be closely following the financial results of McKesson in its upcoming release. The company plans to announce its earnings on August 6, 2025. In that report, analysts expect McKesson to post earnings of $8.23 per share. This would mark year-over-year growth of 4.44%. In the meantime, our current consensus estimate forecasts the revenue to be $96.08 billion, indicating a 21.18% growth compared to the corresponding quarter of the prior year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $37.26 per share and a revenue of $406.16 billion, signifying shifts of +12.74% and +13.12%, respectively, from the last year. Investors should also pay attention to any latest changes in analyst estimates for McKesson. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.08% higher. McKesson is currently a Zacks Rank #2 (Buy). In terms of valuation, McKesson is currently trading at a Forward P/E ratio of 19.19. This signifies a premium in comparison to the average Forward P/E of 17.82 for its industry. We can also see that MCK currently has a PEG ratio of 1.45. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Dental Supplies industry had an average PEG ratio of 1.76 as trading concluded yesterday. The Medical - Dental Supplies industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 29, placing it within the top 12% of over 250 industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
3 hours ago
- Health
- Yahoo
Trump Requests 17 Pharmaceutical Companies to Lower Costs
Press Secretary Karoline Leavitt read President Trump's letter to several pharmaceutical companies, which asked them to provide 'American families immediate relief from the vastly inflated drug prices.'
CTV News
11 hours ago
- Business
- CTV News
Trump pressures 17 pharma CEOs to cut U.S. drug prices
Pills spill in an arrangement photo of prescription Oxycodone in New York. (AP Photo/Mark Lennihan, File) U.S. President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday. Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas. Trump sent the letters to the chief executives of Eli Lilly, Sanofi, Regeneron, Merck & Co, Johnson & Johnson, and AstraZeneca, among others, the White House said. 'Most proposals my Administration has received to 'resolve' this critical issue promised more of the same; shifting blame and requesting policy changes that would result in billions of dollars in handouts to industry,' Trump wrote in the letters, copies of which were posted on his Truth Social account. Shares of Pfizer, Eli Lilly and Gilead Sciences closed down about two per cent each, while the NYSE Arca Pharmaceutical Index fell three per cent on Thursday. Trump called on drugmakers to provide so-called most-favored-nation prices to every patient enrolled in the government Medicaid health program for low-income people, and to guarantee such pricing for new drugs. The policy is aimed at cutting U.S. prescription drug prices to the lowest possible price paid by members of the Organisation for Economic Co-operation and Development, which includes most of the world's largest economies. Trump also said companies must return excess overseas revenue from raising prices in other countries to offset lower prices in the U.S. to American patients and taxpayers through an agreement with the government. He is requiring drugmakers to stipulate they would not offer other developed nations better prices than what they offer the United States, and said his administration would provide ways to cut out middlemen and sell directly to patients, provided they do so at most-favored-nation prices. Trump gave companies until Sept. 29 to respond with binding commitments to those terms. 'If you refuse to step up, we will deploy every tool in our arsenal to protect Americans from abusive drug pricing practices,' he warned. Analysts, lobbyists and drug pricing experts said it seemed unlikely that the pharmaceutical companies would comply with Trump's demand to lower U.S. prices. 'I might expect them to try to determine if any of their current products might be made available via direct sales (one of the requests) at a lower price than currently available in the U.S.,' said Stacie Dusetzina, professor of health policy at Nashville's Vanderbilt University. UBS analyst Trung Huynh said Trump's letters were a repeat of earlier demands and played down any likely industry impact, calling it 'just another shot in the dark.' Trump has already pushed for voluntary changes and some companies have pledged to build new U.S. manufacturing plants. U.S. patients pay by far the most for prescription medicines, often nearly three times more than in other developed nations. The country also invests heavily in pharmaceutical research and development. Drugmakers have said drastic price cuts would stifle innovation. Pharmaceutical companies including Pfizer, Novartis, AbbVie, and German Merck KGaA's U.S. division, EMD Serono, said they were open to working with the Trump administration. Pfizer is working closely with the Trump Administration and Congress to improve access and affordability for American patients, said spokeswoman Amy Rose. 'Our discussions have been productive,' she said. Jeff Mason, Nandita Bose, Patrick Wingrove, Reuters
Wall Street Journal
13 hours ago
- Health
- Wall Street Journal
Trump Requests 17 Pharmaceutical Companies to Lower Costs
Press Secretary Karoline Leavitt read President Trump's letter to several pharmaceutical companies, which asked them to provide 'American families immediate relief from the vastly inflated drug prices.' Photo: Evelyn Hockstein/Reuters
Yahoo
15 hours ago
- Business
- Yahoo
Trump pressures 17 pharma CEOs to cut US drug prices
By Jeff Mason and Nandita Bose WASHINGTON (Reuters) -U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House said on Thursday. Letters were sent to top executives at Eli Lilly, Sanofi, Regeneron, Merck & Co, Johnson & Johnson, and AstraZeneca, among others. Copies of the letters were posted on Trump's Truth Social account. The president is calling on the companies to extend most favored nation pricing to Medicaid, guarantee such pricing for new drugs, and return excess overseas revenue to American patients and taxpayers, without providing details. Trump has given the companies until September 29 to respond with binding commitments to those terms. "According to recent data, the prices that Americans have been paying for brand name drugs are more than three times the price other similarly developed nations pay," said White House press secretary Karoline Leavitt. She added the administration will "deploy every tool in our arsenal" to end "abusive drug pricing practices."
